Gilead stock falls after disappointing lung cancer study results
Sopa Images | Lightrocket | Getty Images Shares of Gilead fell more than 9% on Monday after a key drug from the company did not significantly extend the lives of patients with a certain lung cancer in a late-stage trial. The results are a blow to Gilead, which is working to become a power player … Read more
/cdn.vox-cdn.com/uploads/chorus_asset/file/25442034/2118359708.jpg)
